Home » Newsletters » BioWorld Science

BioWorld Science

July 13, 2011

View Archived Issues

Alnylam files CTA in U.K. for RNAi therapeutic ALN-PCS in severe hypercholesterolemia

Axelar completes phase I/II safety study of AXL-1717 in solid tumors

Transcend-trastuzumab conjugate BT-2111 shows promise as therapeutic for metastatic breast cancer

Adalimumab is beneficial in hidradenitis suppurativa in phase II study

High palladin levels in tumor-associated stromata predict poor survival in renal cell carcinoma

Briakinumab is superior to etanercept in treating chronic plaque psoriasis

SCYX-7158 shows promise in model of stage 2 human African trypanosomiasis

Merck & Co. discloses new tyrosine-protein kinase SYK inhibitors

Universitat de Barcelona and CSIC present new glucosylceramidase inhibitors

Sunovion claims new metabotropic glutamate mGlu5 receptor receptor ligands

Astellas to transfer rights for minor tranquilizer Balance to Maruishi Pharmaceutical

Biogen Idec and Unilabs collaborate on companion diagnostic test for Tysabri-treated patients

Novel dipeptidyl peptidase 1 inhibitors reported by Janssen Pharmaceutica

Titan Pharmaceuticals reports topline results from phase III Probuphine trial

New glucokinase activators patented by Astellas Pharma

ATX-101 is safe and reduces submental fat in phase II trial

Phase II oral interferon study for prevention of hepatitis C relapse progresses

Sunshine Biopharma's Adva-27a effectively kills multidrug-resistant breast cancer cells in vitro

Enrollment complete in first cohort of Advaxis' phase II ADXS-HPV study

Gamida Cell-Teva joint venture clear to continue accrual in phase III StemEx trial

Micromet and Amgen form BiTE antibody collaboration

DMC completes data review from 535 participants of phase III trial HEAT

Zuplenz available for licensing to new commercialization partners

Arena Pharmaceuticals reports phase I findings on APD-811 in PAH

Zogenix and Durect enter development agreement for needle-free formulation of risperidone

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...